P-gp Inhibition Results 16x Faster Than LC-MS/MS

In this month’s Rapid Communications in Mass Spectrometry, researchers from Bristol-Myers Squibb write about their achievement of an early liability P-gp inhibition screen that generates more than a thousand samples per day.

You’ll need to have a login to the Wiley online library to see the full article, but wanted to share an excerpt anyway: “The RF-MS/MS method was more than 16 times faster than the LC-MS/MS method but demonstrated similar sensitivity, selectivity, reproducibility, linearity and robustness. P-gp inhibition results of multiple validation compounds obtained with this RF-MS/MS method were in agreement with those generated by both the LC-MS/MS method and the ³H-radiolabel assay. This method has been successfully deployed to assess P-gp inhibition potential as an important early liability screen for drug–transporter interaction.”

To learn more, visit our web page about RapidFire ADME analysis services, or read the article “Ultra-fast mass spectrometry based bio-analytical method for digoxin supporting an in vitro P-glycoprotein (P-gp) inhibition screen”

Ultrafast mass spectrometry based bioanalytical method for digoxin supporting an in vitro P-glycoprotein (P-gp) inhibition screenUltrafast mass spectrometry based bioanalytical method for digoxin supporting an in vitro P-glycoprotein (P-gp) inhibition screen

Advertisement